Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.

Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

Abstract: The present disclosure relates to compounds of formulae (I)-(VI) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.

Abstract: The present disclosure relates to thiazolo-pyridine, oxazolo-pyridine, pyrrolo-pyridine, pyrrolo-pyrazine and pyrrolo-pyrimidine compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.

Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.

Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

Abstract: The present invention relates to methods of stimulating osteoblast function with a PYK2 inhibitor in subjects with osteoporosis, bone fractures, non-unions, pseudoarthroses, periodontal disease or other disorders of bone metabolism. Optionally, the method further comprises administration of a second therapeutic bone agent. The present invention also relates to methods to identify a PYK2 inhibitor effective as a therapeutic bone agent comprising administering a test agent to an osteoblast-like cell and determining if osteoblast function is stimulated. Optionally, the identifying method further comprises contacting the test agent with PYK2 and determining if PYK2 activity is inhibited.

Abstract: This invention relates to human chondrocyte activity (growth)/differentiation/production of extracellular matrix) and to the effect of Sox9 transcription factor and Col2 enhancer as a measure for such activity. It also relates to a chimeric cell and assay utilizing such cell useful in predicting the effect of sample compounds on chondrocyte activity as measured by Sox9 and Col2 expression/activity.

Abstract: This invention relates to in vitro screening and assay methods for the selection of anti-inflammatory compounds that exhibit minimized effects on the differentiation of human osteoblasts.

Abstract: The present invention relates to members of the family of proteins known as ADAMTS proteins, the new members being designated ADAMTS-E polypeptides. The invention also relates to polynucleotides encoding ADAMTS-E, antibodies to ADAMTS-E, assays for studying the function of ADAMTS-E, assays for determining stimulators or inhibitors of ADAMTS-E, and to the use of ADAMTS-E polypeptides or polynucleotides in diagnostic, biotherapeutic, or gene therapy methods.

Abstract: The present invention relates to a member of the family of proteins known as ADAMTS proteins, the new member being designated ADAMTS-SI. The invention also relates to polynucleotides encoding ADAMTS-SI, antibodies to ADAMTS-SI, assays for studying the function of ADAMTS-SI, assays for determining agonists or antagonists of ADAMTS-SI, and to the use of ADAMTS-SI polypeptides or polynucleotides in diagnostic, biotherapeutic, or gene therapy methods.

Abstract: The present invention relates to a member of the family of proteins known as ADAMTS proteins, the new member being designated ADAMTS-M. The invention also relates to polynucleotides encoding ADAMTS-M, antibodies to ADAMTS-M, assays for studying the function of ADAMTS-M, assays for determining agonists or antagonists of ADAMTS-M, and to the use of ADAMTS-M polypeptides or polynucleotides in diagnostic, biotherapeutic, or gene therapy methods.

Abstract: This present invention concerns polypeptide molecules comprising human p53 response protein PIGI-1.

Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of p53 response protein PIGI-1, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials are disclosed. The invention also concerns polypeptide molecules comprising all or part of p53 response protein PIGI-1, and methods for producing these polypeptide molecules.